Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 9277-9290

  Ou, H J ^a   Huang, G ^a   Liu, W ^a   Ma, X L ^a   Wei, Y ^a   Zhou, T ^a   Pan, Z M ^a  

^a SHIHEZI UNIVERSITY   (China)

Author keywords

APOA5 A4 C3 A1 gene cluster; Apolipoprotein B; Dyslipidemia; Gene polymorphism

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOLIPOPROTEIN A;

ADULT; APOA1 GENE; APOA4 GENE; APOA5 GENE; APOB GENE; APOC3 GENE; ARTICLE; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENETIC CORRELATION; GENETIC RISK; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; ALLELE; GENETIC ASSOCIATION STUDY; GENETICS; HAPLOTYPE; MIDDLE AGED; MULTIGENE FAMILY; RISK FACTOR;

ALLELES; APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CASE-CONTROL STUDIES; DYSLIPIDEMIAS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84939160370     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.August.10.8     Document Type: Article

References (11)

1. Bhanushali AA and Das BR (2010). Influence of genetic variants in the apolipoprotein A5 and C3 gene on lipids, lipoproteins, and its association with coronary artery disease in Indians. J. Community Genet. 1: 139-148.
2. Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, et al. (2011). Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 219: 737-742.
3. Chien KL, Fang WH, Wen HC, Lin HP, et al. (2008). APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese. Clin. Chim. Acta 390: 56-62.
4. Dallongeville J, Cottel D, Montaye M, Codron V, et al. (2006). Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men. Int. J. Cardiol. 106: 152-156.
5. Joint Committee for Developing Chinese guidelines on prevention and treatment of dyslipidemia in adults (2007). Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chin. J. Cardiol. 35: 390-419.
6. Liu Y, Ordovas JM, Gao G, Province M, et al. (2009). Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet. Genomics 19: 161-169.
7. Rudkowska I, Dewailly E, Hegele RA, Boiteau V, et al. (2013). Gene-diet interactions on plasma lipid levels in the Inuit population. Br. J. Nutr. 109: 953-961.
8. Tan A, Sun J, Xia N, Qin X, et al. (2012). A genome-wide association and gene-environment interaction study for serum triglycerides levels in a healthy Chinese male population. Hum. Mol. Genet. 21: 1658-1664.
9. Yin RX, Li YY and Lai CQ (2011). Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels. Lipids Health Dis. 10: 140.
10. Zhang Z, Peng B, Gong RR, Gao LB, et al. (2011). Apolipoprotein A5 polymorphisms and risk of coronary artery disease: a meta-analysis. Biosci. Trends 5: 165-172.
11. Zheng QL and Zhu W (2007). Hyperlipidemia. Chinese Medical Science Press., Beijing.